Wells Fargo analyst Vik Chopra has maintained their bullish stance on NPCE stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vik Chopra has given his Buy rating due to a combination of factors that highlight NeuroPace’s potential despite some challenges. The management team expressed confidence in their recent discussions, emphasizing the positive outcomes from the NAUTILUS study, particularly the achievement of the primary safety endpoint and promising secondary endpoints. Although the primary effectiveness endpoint did not reach statistical significance, the study showed significant response in a majority subset of participants, indicating potential for future success.
Moreover, NeuroPace’s management is in active discussions with the FDA and anticipates filing the NAUTILUS trial data in the second half of 2025. The FDA’s openness to the data, due to an unmet clinical need and breakthrough status, suggests a favorable regulatory environment. Despite the missed primary effectiveness endpoint, the company sees minimal risk to its commercial momentum and believes in the strength of its current strategy and market position, which supports the Buy rating.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $20.00 price target.